AU2003210210A1 - The use of omega-3 polyunsaturated acids ethyl esters in patients suffering from heart failure - Google Patents

The use of omega-3 polyunsaturated acids ethyl esters in patients suffering from heart failure

Info

Publication number
AU2003210210A1
AU2003210210A1 AU2003210210A AU2003210210A AU2003210210A1 AU 2003210210 A1 AU2003210210 A1 AU 2003210210A1 AU 2003210210 A AU2003210210 A AU 2003210210A AU 2003210210 A AU2003210210 A AU 2003210210A AU 2003210210 A1 AU2003210210 A1 AU 2003210210A1
Authority
AU
Australia
Prior art keywords
omega
heart failure
patients suffering
ethyl esters
acids ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003210210A
Inventor
Jadranka Rogan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
VICTORIX ASSETS Ltd
Original Assignee
VICTORIX ASSETS Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by VICTORIX ASSETS Ltd filed Critical VICTORIX ASSETS Ltd
Publication of AU2003210210A1 publication Critical patent/AU2003210210A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AU2003210210A 2002-02-12 2003-02-05 The use of omega-3 polyunsaturated acids ethyl esters in patients suffering from heart failure Abandoned AU2003210210A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT2002MI000269A ITMI20020269A1 (en) 2002-02-12 2002-02-12 USE OF OMEGA-3 POLYUNSATURATED ACID ETHYL STERES IN PATIENTS WITH HEART INSUFFICIENCY
ITMI2002A000269 2002-02-12
PCT/EP2003/001108 WO2003068216A1 (en) 2002-02-12 2003-02-05 The use of omega-3 polyunsaturated acids ethyl esters in patients suffering from heart failure

Publications (1)

Publication Number Publication Date
AU2003210210A1 true AU2003210210A1 (en) 2003-09-04

Family

ID=11449201

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003210210A Abandoned AU2003210210A1 (en) 2002-02-12 2003-02-05 The use of omega-3 polyunsaturated acids ethyl esters in patients suffering from heart failure

Country Status (4)

Country Link
EP (1) EP1474125A1 (en)
AU (1) AU2003210210A1 (en)
IT (1) ITMI20020269A1 (en)
WO (1) WO2003068216A1 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9901809D0 (en) 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
ITMI20022511A1 (en) * 2002-11-26 2004-05-27 Victorix Assets Ltd USE OF PHARMACEUTICAL COMPOSITIONS CONTAINING ETHYL ESTERS OF OMEGA-3 POLYUNSATURATED ACIDS IN THE ORDER OF ATRIAL FIBRILLATION.
GB0403247D0 (en) 2004-02-13 2004-03-17 Tillotts Pharma Ag A pharmaceutical composition
RU2437583C2 (en) * 2005-12-21 2011-12-27 Бруди Текнолоджи, С.Л. Application of dha, epa or epa obtained from dha for treatment of pathology associated with oxidative damage of cell, as well as their non-therapeutic application
ES2277557B1 (en) 2005-12-21 2008-07-01 Proyecto Empresarial Brudy, S.L. USE OF DOCOSAHEXAENOIC ACID FOR THE TREATMENT OF OXIDATIVE CELL DAMAGE.
EP3578177A1 (en) 2008-09-02 2019-12-11 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
EP2596786B1 (en) 2009-02-10 2019-11-27 Amarin Pharmaceuticals Ireland Limited Use of eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia
CN110538148A (en) 2009-03-09 2019-12-06 巴斯夫股份公司 Compositions comprising fatty acid oil mixtures and surfactants, methods and uses thereof
EP3563842A1 (en) 2009-04-29 2019-11-06 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
RU2538691C2 (en) 2009-04-29 2015-01-10 Амарин Фарма, Инк. Stable pharmaceutical compositions and methods for using them
LT3318255T (en) 2009-06-15 2021-05-25 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating stroke in a subject on concomitant statin therapy
CA2775339C (en) 2009-09-23 2017-03-28 Amarin Corporation Plc Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
NZ744990A (en) 2010-11-29 2019-10-25 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
CA2826663A1 (en) 2011-02-07 2012-08-16 Mochida Pharmaceutical Co., Ltd. Therapeutic agent for diastolic congestive heart failure
EP2775837A4 (en) 2011-11-07 2015-10-28 Amarin Pharmaceuticals Ie Ltd Methods of treating hypertriglyceridemia
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
EP2800469B1 (en) 2012-01-06 2021-08-25 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject
EP4342546A3 (en) 2012-06-29 2024-05-22 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
TW201900160A (en) 2017-05-19 2019-01-01 愛爾蘭商艾瑪琳製藥愛爾蘭有限公司 Compositions and Methods for Lowering Triglycerides in a Subject Having Reduced Kidney Function
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
FI4056176T3 (en) 2018-09-24 2024-05-30 Amarin Pharmaceuticals Ie Ltd Methods of reducing the risk of cardiovascular events in a subject
AU2022263358A1 (en) 2021-04-21 2023-11-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1308613B1 (en) * 1999-02-17 2002-01-09 Pharmacia & Upjohn Spa ESSENTIAL FATTY ACIDS IN THE PREVENTION OF CARDIOVASCULAR EVENTS.
ATE305810T1 (en) * 2000-05-22 2005-10-15 Pro Aparts Investimentos E Con PHARMACEUTICAL COMPOSITION CONTAINING FATTY ACID WHICH IS AT LEAST 80 Wt. CONTAINS EPA AND DHA
ITMI20010129A1 (en) * 2001-01-25 2002-07-25 Pharmacia & Upjohn Spa ESSENTIAL FATTY ACIDS IN THE THERAPY OF HEART INSUFFICIENCY AND HEART FAILURE

Also Published As

Publication number Publication date
ITMI20020269A1 (en) 2003-08-12
EP1474125A1 (en) 2004-11-10
WO2003068216A1 (en) 2003-08-21
ITMI20020269A0 (en) 2002-02-12

Similar Documents

Publication Publication Date Title
AU2003210210A1 (en) The use of omega-3 polyunsaturated acids ethyl esters in patients suffering from heart failure
AU2003217759A1 (en) Omega-3 fatty acids or omega-3 phosphatidylcholine in the treatment of depression
AU2003259904A1 (en) Coated polyunsaturated fatty acid-containing particles and coated liquid pharmaceutical-containing particles
PL363269A1 (en) Essential n-3 fatty acids in cardiac insufficiency and heart failure therapy
GB2409644B (en) Formulation comprising eicosapentaenoic acid or an ester thereof and a triterpene or an ester thereof
AU2002224914A1 (en) Method and device for the diagnosis and therapy of chronic heart failure
IL172170A0 (en) Propionic acid derivatives useful in the treatment of lipid disorders
AU2003208920A1 (en) Fatty acid-containing compositions and methods for the treatment of cytokine mediated disorders
AU2003201693A1 (en) Non-aromatic 17.alpha.-esters of androstane-17.beta.-carboxylate esters as anti-inflammatory agents
AU9164198A (en) Use of organic acid esters in dietary fat
HK1073650A1 (en) Methods for producing substituted acrylic acid esters and use of the latter for producing substituted
IL151014A0 (en) Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
HK1059386A1 (en) Potentiation of therapeutic effects of polyunsaturated fatty acids
EP1551382A4 (en) Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation
HK1072609A1 (en) New etonogestrel esters
AU2003223930A1 (en) Pharmaceutical use of boronic acids and esters thereof
AU2003208769A1 (en) Methods for the production of unsaturated fatty acids
AU2003304576A1 (en) Cis-hydrogenated fatty acid coating of medical devices
AU2003222083A1 (en) Acid and ester compounds and methods of using the same
AU2058701A (en) Esters of vitamin D3 and uses thereof
AU2003290799A1 (en) 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
HK1072568A1 (en) Use of new etonogestrel esters
ITMI20022511A1 (en) USE OF PHARMACEUTICAL COMPOSITIONS CONTAINING ETHYL ESTERS OF OMEGA-3 POLYUNSATURATED ACIDS IN THE ORDER OF ATRIAL FIBRILLATION.
AU2003292876A1 (en) The use of succinate derivative esters for the treatment of dementia
AU2003299920A1 (en) Production and purification of esters of conjugated linoleic acids

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase